Search by Drug Name or NDC
NDC 00006-4119-03 GARDASIL 9 40; 60; 40; 20; 20; 20; 20; 20; 30 ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL Details
GARDASIL 9 40; 60; 40; 20; 20; 20; 20; 20; 30 ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL
GARDASIL 9 is a INTRAMUSCULAR INJECTION, SUSPENSION in the VACCINE category. It is labeled and distributed by Merck Sharp & Dohme LLC. The primary component is HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 31 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 33 L1.
MedlinePlus Drug Summary
Why get vaccinated? HPV (human papillomavirus) vaccine can prevent infection with some types of human papillomavirus. HPV infections can cause certain types of cancers, including: cervical, vaginal, and vulvar cancer in females penile cancer in males anal cancer in both men and women cancers of tonsils, base of tongue, and back of throat (oropharyngeal cancer) in both men and women HPV infections can also cause anogenital warts. HPV vaccine can prevent over 90% of cancers caused by HPV. HPV is spread through intimate skin-to-skin or sexual contact. HPV infections are so common that nearly all people will get at least one type of HPV at some time in their lives. Most HPV infections go away on their own within 2 years. But sometimes HPV infections will last longer and can cause cancers later in life.
Related Packages: 00006-4119-03Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Human Papillomavirus (HPV) Vaccine
Product Information
| NDC | 00006-4119 |
|---|---|
| Product ID | 0006-4119_24b02bdc-d842-4667-93c5-b5ddfac71ab8 |
| Associated GPIs | 17100065501800 |
| GCN Sequence Number | 073199 |
| GCN Sequence Number Description | HPV vaccine 9-valent/PF VIAL 0.5 ML INTRAMUSC |
| HIC3 | W7B |
| HIC3 Description | VIRAL/TUMORIGENIC VACCINES |
| GCN | 37567 |
| HICL Sequence Number | 041619 |
| HICL Sequence Number Description | HUMAN PAPILLOMAVIRUS VACCINE, 9-VALENT/PF |
| Brand/Generic | Brand |
| Proprietary Name | GARDASIL 9 |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Human Papillomavirus 9-valent Vaccine, Recombinant |
| Product Type | VACCINE |
| Dosage Form | INJECTION, SUSPENSION |
| Route | INTRAMUSCULAR |
| Active Ingredient Strength | 40; 60; 40; 20; 20; 20; 20; 20; 30 |
| Active Ingredient Units | ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL |
| Substance Name | HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 31 L1 CAPSID PROTEIN ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 33 L1 |
| Labeler Name | Merck Sharp & Dohme LLC |
| Pharmaceutical Class | Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Inactivated Human Papillomavirus Vaccine [EPC], Inactivated Human Papillomavirus Vaccine [EPC], Inactivated Human Papilloma |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA125508 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00006-4119-03 (00006411903)
| NDC Package Code | 0006-4119-03 |
|---|---|
| Billing NDC | 00006411903 |
| Package | 10 VIAL, SINGLE-DOSE in 1 CARTON (0006-4119-03) / .5 mL in 1 VIAL, SINGLE-DOSE (0006-4119-01) |
| Marketing Start Date | 2014-12-10 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |